{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:30:16Z","timestamp":1787236216446,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In recent decades, tranexamic acid (TXA) antifibrinolytic therapy before aneurysm clipping or embolization has been widely reported, but its safety and efficacy remain controversial. This meta-analysis evaluated the efficacy and safety of TXA therapy in aneurysmal subarachnoid hemorrhage (aSAH) patients, aiming to improve the evidence-based medical knowledge of treatment options for such patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pubmed, Web of Science, and Cochrane Library databases were searched up to 1 March 2021 for randomized controlled trials (RCTs). We extracted safety and efficacy outcomes and performed a meta-analysis using the Review Manager software. We performed two group analyses of TXA duration and daily dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten RCT studies, enrolling a total of 2,810 participants (1,410 with and 1,400 without TXA therapy), matched the selection criteria. In the TXA duration group: TXA did not reduce overall mortality during the follow-up period [RR 1.00 (95% CI 0.81\u20131.22)]. The overall rebleeding rate in the TXA group was 0.53 times that of the control group, which was statistically significant [RR 0.53 (95% CI 0.39\u20130.71)]. However, an RR of 0.43 was not statistically significant in the subgroup analysis of short-term therapy [RR 0.43 (95% CI 0.13\u20131.39)]. The overall incidence of hydrocephalus was significantly higher in the TXA group than in the control group [RR 1.13 (95% CI 1.02\u20131.24)]. However, the trend was not statistically significant in the subgroup analysis [short-term: RR 1.10 (95% CI 0.99\u20131.23); long-term: RR 1.22 (95% CI 0.99\u20131.50)]. Treatment with TXA did not cause significant delayed cerebral ischemia [RR 1.18 (95% CI 0.89\u20131.56)], and its subgroup analysis showed an opposite and insignificant effect [short-term: RR 0.99 (95% CI 0.79\u20131.25); long-term: RR 1.38 (95% CI 0.86\u20132.21)]. Results in the daily dose group were consistent with those in the TXA duration group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tranexamic acid does not reduce overall mortality in patients with aSAH, nor does it increase the incidence of delayed cerebral ischemia. Tranexamic acid in treating aSAH can reduce the incidence of rebleeding. However, there is no statisticalsignificance in the ultra-early short-term and low daily dose TXA therapy, which may be due to the lack of relevant studies, and more RCT experiments are needed for further study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration:<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.asp?<\/jats:ext-link>\n                      PROSPERO, identifier: 244079.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2021.710495","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T23:30:07Z","timestamp":1642980607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and Efficacy of Tranexamic Acid in Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Junwei","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","article-title":"Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis","volume":"76","author":"Etminan","year":"2019","journal-title":"JAMA Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1161\/STROKEAHA.110.581975","article-title":"Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage","volume":"41","author":"Al-Khindi","year":"2010","journal-title":"Stroke."},{"key":"B3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40263-019-00608-4","article-title":"Tranexamic acid in cerebral hemorrhage: a meta-analysis and systematic review","volume":"33","author":"Hu","year":"2019","journal-title":"CNS Drugs."},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD001245","DOI":"10.1002\/14651858.CD001245.pub2","article-title":"Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage","volume":"8","author":"Baharoglu","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3171\/jns.2002.97.4.0771","article-title":"Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study","volume":"97","author":"Hillman","year":"2002","journal-title":"J Neurosurg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1212\/wnl.54.1.77","article-title":"Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial","volume":"54","author":"Roos","year":"2000","journal-title":"STAR Study Group Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/STROKEAHA.117.019328","article-title":"Predictors of in-hospital death after aneurysmal subarachnoid hemorrhage: analysis of a nationwide database (Swiss SOS [Swiss Study on Aneurysmal Subarachnoid Hemorrhage])","volume":"49","author":"Stienen","year":"2018","journal-title":"Stroke."},{"key":"B8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/MBC.0000000000000845","article-title":"No hyperfibrinolysis following subarachnoid or intracerebral haemorrhage: a prospective cohort study","volume":"30","author":"Lauridsen","year":"2019","journal-title":"Blood Coagul Fibrinolysis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJM198408163110703","article-title":"Antifibrinolytic treatment in subarachnoid hemorrhage","volume":"311","author":"Vermeulen","year":"1984","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jcp.33.Suppl_14.68","article-title":"Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage","volume":"14","author":"Fodstad","year":"1980","journal-title":"J Clin Pathol Suppl (R Coll Pathol)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ana.410030607","article-title":"Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial","volume":"3","author":"Chandra","year":"1978","journal-title":"Ann Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00415-014-7365-0","article-title":"Time intervals from subarachnoid hemorrhage to rebleed","volume":"261","author":"Germans","year":"2014","journal-title":"J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0140-6736(20)32518-6","article-title":"Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial","volume":"397","author":"Post","year":"2021","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials."},{"key":"B15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12028-019-00737-0","article-title":"Prioritization and timing of outcomes and endpoints after aneurysmal subarachnoid hemorrhage in clinical trials and observational studies: proposal of a multidisciplinary research group","volume":"30","author":"Stienen","year":"2019","journal-title":"Neurocrit Care."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0211868","DOI":"10.1371\/journal.pone.0211868","article-title":"Short-term tranexamic acid treatment reduces in-hospital mortality in aneurysmal sub-arachnoid hemorrhage: A multicenter comparison study","volume":"14","author":"Post","year":"2019","journal-title":"PLoS ONE."},{"key":"B19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1161\/01.str.24.6.809","article-title":"Amount of blood on computed tomography as an independent predictor after aneurysm rupture","volume":"24","author":"Brouwers","year":"1993","journal-title":"Stroke."},{"key":"B20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/BF01407517","article-title":"Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid","volume":"103","author":"Tsementzis","year":"1990","journal-title":"Acta Neurochir (Wien)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01402177","article-title":"Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study","volume":"102","author":"Tsementzis","year":"1990","journal-title":"Acta Neurochir (Wien)."},{"key":"B22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1227\/00006123-198102000-00004","article-title":"Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial","volume":"8","author":"Fodstad","year":"1981","journal-title":"Neurosurgery."},{"key":"B23","first-page":"131","article-title":"Antifibrinolytics and subarachnoid hemorrhage-results from 2 controlled clinicaltrials using tranexamic acid (AMCA)","volume":"51","author":"Fodstad","year":"1979","journal-title":"Acta Neurochir."},{"key":"B24","first-page":"247","article-title":"Effect of tranexamic acid (AMCA) on radiological cerebral vasospasm following subarachnoid hemorrhage","volume":"42","author":"Fodstad","year":"1978","journal-title":"Acta Neurochir."},{"key":"B25","first-page":"9","article-title":"Tranexamic acid in the preoperative management of ruptured intracranial aneurysms","volume":"10","author":"Fodstad","year":"1978","journal-title":"Surg Neurol."},{"key":"B26","first-page":"254","article-title":"Effect of tranexamic acid on fatal rebleeds after subarachnoid hemorrhage - double-blind-study","volume":"5767","author":"Kaste","year":"1978","journal-title":"Acta Neurol Scand."},{"key":"B27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1161\/01.str.10.5.519","article-title":"Tranexamic acid in subarachnoid hemorrhage. A double-blind study","volume":"10","author":"Kaste","year":"1979","journal-title":"Stroke."},{"key":"B28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/bmj.1.6118.945","article-title":"Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?","volume":"1","author":"Maurice-Williams","year":"1978","journal-title":"Br Med J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ana.410020310","article-title":"Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial","volume":"2","author":"van Rossum","year":"1977","journal-title":"Ann Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ajem.2021.09.047","article-title":"Tranexamic acid for subarachnoid hemorrhage: A systematic review and meta-analysis","volume":"50","author":"Feng","year":"2021","journal-title":"Am J Emerg Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3171\/jns.1988.68.6.0901","article-title":"Significance of \u201cultra-early\u201d rebleeding in subarachnoid hemorrhage","volume":"68","author":"Hillman","year":"1988","journal-title":"J Neurosurg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/01.str.32.5.1176","article-title":"Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management","volume":"32","author":"Ohkuma","year":"2001","journal-title":"Stroke."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/01.str.20.12.1674","article-title":"Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage","volume":"20","author":"Wijdicks","year":"1989","journal-title":"Stroke."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001245","article-title":"Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage","author":"Roos","year":"2003","journal-title":"Cochrane Database Syst Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/brain\/124.2.249","article-title":"Subarachnoid haemorrhage: diagnosis, causes and management","volume":"124","author":"van Gijn","year":"2001","journal-title":"Brain."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1212\/wnl.44.10.1851","article-title":"Predictive factors for deterioration from hydrocephalus after subarachnoid hemorrhage","volume":"44","author":"Vermeij","year":"1994","journal-title":"Neurology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1212\/CON.0000000000000679","article-title":"Subarachnoid Hemorrhage","volume":"24","author":"Muehlschlegel","year":"2018","journal-title":"Continuum (Minneap Minn)."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10143-020-01324-0","article-title":"Tranexamic acid in neurosurgery: a controversy indication-review","volume":"44","author":"de Faria","year":"2021","journal-title":"Neurosurg Rev"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.710495\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T23:30:15Z","timestamp":1642980615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.710495\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":38,"alternative-id":["10.3389\/fneur.2021.710495"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.710495","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"article-number":"710495"}}